flyExclusive, Inc. (FLYX)
NYSEAMERICAN: FLYX · Real-Time Price · USD
2.350
-0.044 (-1.84%)
Aug 1, 2025, 4:00 PM - Market closed
Verve Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Verve Therapeutics.
Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Verve Therapeutics.
Recommendation Trends
| Rating | Feb '24 |
|---|---|
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Feb 22, 2024 |
| BTIG | BTIG | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +282.98% | Jan 23, 2024 |
Financial Forecast
Revenue This Year
420.44M
from 327.27M
Increased by 28.47%
Revenue Next Year
514.79M
from 420.44M
Increased by 22.44%
EPS This Year
-0.21
from -1.07
EPS Next Year
-0.03
from -0.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 432.8M | 529.9M | 536.3M |
| Avg | 420.4M | 514.8M | 521.0M |
| Low | 404.0M | 494.6M | 500.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 32.2% | 26.0% | 4.2% |
| Avg | 28.5% | 22.4% | 1.2% |
| Low | 23.4% | 17.6% | -2.8% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -0.22 | -0.03 |
| Avg | -0.21 | -0.03 |
| Low | -0.21 | -0.03 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.